Repro Med Systems Inc (KRMD) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Repro Med Systems Inc (KRMD) has a cash flow conversion efficiency ratio of 0.001x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($14.66K) by net assets ($16.92 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Repro Med Systems Inc defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Repro Med Systems Inc - Cash Flow Conversion Efficiency Trend (1996–2025)
This chart illustrates how Repro Med Systems Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Repro Med Systems Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Repro Med Systems Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sierra Metals Inc.
TO:SMT
|
0.249x |
|
Digital Asset Acquisition Corp.
NASDAQ:DAAQ
|
-0.003x |
|
Korea Air Svc
KO:005430
|
0.047x |
|
Falcon Oil & Gas Ltd
F:FAC
|
-0.012x |
|
Indian Hume Pipe Company Limited
NSE:INDIANHUME
|
-0.005x |
|
Symphony International Holdings Ltd
LSE:SIHL
|
-0.006x |
|
PULSION Medical Systems SE
MU:PUS
|
0.160x |
|
Honma Golf Limited
F:HF5
|
0.008x |
Annual Cash Flow Conversion Efficiency for Repro Med Systems Inc (1996–2025)
The table below shows the annual cash flow conversion efficiency of Repro Med Systems Inc from 1996 to 2025. For the full company profile with market capitalisation and key ratios, see Repro Med Systems Inc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $17.05 Million | $462.40K | 0.027x | +242.64% |
| 2024-12-31 | $16.81 Million | $-319.72K | -0.019x | +92.09% |
| 2023-12-31 | $20.35 Million | $-4.89 Million | -0.240x | -39.33% |
| 2022-12-31 | $31.33 Million | $-5.40 Million | -0.173x | -45.79% |
| 2021-12-31 | $36.50 Million | $-4.32 Million | -0.118x | -475.63% |
| 2020-12-31 | $36.16 Million | $-743.32K | -0.021x | -172.05% |
| 2019-12-31 | $11.24 Million | $320.62K | 0.029x | -82.72% |
| 2018-12-31 | $8.96 Million | $1.48 Million | 0.165x | +40.73% |
| 2017-12-31 | $7.67 Million | $899.91K | 0.117x | +336.21% |
| 2016-12-31 | $6.68 Million | $-331.62K | -0.050x | -117.56% |
| 2015-12-31 | $6.77 Million | $1.91 Million | 0.283x | +114.76% |
| 2014-12-31 | $6.27 Million | $826.10K | 0.132x | -28.37% |
| 2013-12-31 | $5.19 Million | $954.39K | 0.184x | +2.05% |
| 2012-12-31 | $4.36 Million | $784.79K | 0.180x | +14.10% |
| 2011-12-31 | $3.55 Million | $560.60K | 0.158x | -67.34% |
| 2010-12-31 | $2.13 Million | $1.03 Million | 0.483x | +30.72% |
| 2009-12-31 | $1.03 Million | $382.30K | 0.370x | -50.62% |
| 2008-12-31 | $705.09K | $528.18K | 0.749x | +483.59% |
| 2007-12-31 | $-602.26K | $117.61K | -0.195x | -247.35% |
| 2006-12-31 | $-645.83K | $-85.59K | 0.133x | -45.57% |
| 2005-12-31 | $-569.82K | $-138.75K | 0.243x | -51.70% |
| 2004-12-31 | $-380.26K | $-191.69K | 0.504x | +150.37% |
| 2003-12-31 | $-173.46K | $-34.92K | 0.201x | -32.76% |
| 2002-12-31 | $61.19K | $18.32K | 0.299x | +315.55% |
| 2001-12-31 | $337.38K | $-46.87K | -0.139x | +29.35% |
| 2000-12-31 | $694.45K | $-136.56K | -0.197x | -234.46% |
| 1999-12-31 | $657.91K | $96.22K | 0.146x | +171.80% |
| 1998-12-31 | $540.00K | $-110.00K | -0.204x | -15.43% |
| 1997-12-31 | $1.87 Million | $-330.00K | -0.176x | -266.50% |
| 1996-12-31 | $2.17 Million | $230.00K | 0.106x | -- |
About Repro Med Systems Inc
KORU Medical Systems, Inc. develops, manufactures, and commercializes subcutaneous infusion solutions primarily for the subcutaneous drug delivery market in the United States and internationally. The company offers the FREEDOM infusion systems to deliver therapies to patients with chronic illnesses, such as primary immunodeficiency diseases (PIDD), chronic inflammatory demyelinating polyneuropath… Read more